Insiders Snap Up $54M in Biotech and Offshore Driller Stocks
In the past week or so, some public offerings prompted huge insider buying. However, these were not the only notable insider purchases recently.
Arcutis Biotherapeutics Inc is a biopharmaceutical firm dedicated to crafting and bringing to market treatments for skin conditions. With a leading product, ARQ-151, aimed at addressing plaque psoriasis and atopic dermatitis, the company is at the forefront of dermatological innovation. Their pipeline also includes solutions for scalp psoriasis, seborrheic dermatitis, hand eczema, vitiligo, and alopecia areata, showcasing their commitment to tackling a wide range of dermatological challenges. Founded in 2016 and based in Westlake Village, California, Arcutis is pushing the boundaries of skin health.
In the past week or so, some public offerings prompted huge insider buying. However, these were not the only notable insider purchases recently.
Wednesday’s top analyst upgrades and downgrades included Allegro, Jinkosolar, Masco, Micron Technology, Plug Power, Smith & Wesson and Virgin Galactic.
Thursday's top analyst upgrades and downgrades included Airbnb, CrowdStrike, DoorDash, Ford, Intuit, Lumber Liquidators, Occidental Petroleum, T-Mobile, Twilio, Uber and UBS.
Thursday's top analyst upgrades and downgrades included Arcutis Biotherapeutics, DraftKings, First Solar, InflaRx, Livent, Medtronic, NextEra Energy Partners, Roku, Snowflake and Tesla.
24/7 Wall St. tracked six new secondary offerings that were announced after the close on Tuesday, September 29, 2020.